600276
vs
NOVN
600276
NOVN
Over the past 12 months, Jiangsu Hengrui Pharmaceuticals Co Ltd has underperformed NOVN, delivering a return of +17% compared to the NOVN's +30% growth.
This Feature is Available on
Paid Plans
Paid Plans
This Feature is Available on Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
14-day money-back guarantee
Smart Verdict
AI-Powered
Not Sure Which Stock Wins?
Let AI Decide.
Let AI Decide.
600276
NOVN
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Summarizing...
We need a little more time to summarize the results
Valuation Comparison
Intrinsic Value
52.08
CNY
Overvaluation 9%
NOVN
Intrinsic Value
107.36
CHF
Overvaluation 9%
| Company | Last Price | Intrinsic Value | DCF Value | Multiples-Based Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
57.47
CNY
|
|||||
|
Novartis AG
SIX:NOVN
|
118.1
CHF
|
|||||
No Stocks Selected
Compare the stock's valuation with its competitors.
Valuation Scenario:
Growth Comparison
Growth Over Time
600276, NOVN
600276, NOVN
Revenue
www.alphaspread.com
No Stocks Selected
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
Revenue
|
|||||||||||
|
|
Novartis AG
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
No Stocks Selected
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
600276, NOVN
600276, NOVN
Free Cash Flow
www.alphaspread.com
No Stocks Selected
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
|||||||||
|
|
Novartis AG
SIX:NOVN
|
|||||||||
No Stocks Selected
Compare company's free cash flow with its competitors.
Gross Margin
Jiangsu Hengrui Pharmaceuticals Co Ltd
86.2%
NOVN
75.8%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd | ||||
|
|
Novartis AG | ||||
Operating Margin
Jiangsu Hengrui Pharmaceuticals Co Ltd
27%
NOVN
33.2%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd | ||||
|
|
Novartis AG | ||||
Net Margin
Jiangsu Hengrui Pharmaceuticals Co Ltd
24.4%
NOVN
24.8%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd | ||||
|
|
Novartis AG | ||||
FCF Margin
Jiangsu Hengrui Pharmaceuticals Co Ltd
26.2%
NOVN
27.1%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd | ||||
|
|
Novartis AG | ||||
ROE
Jiangsu Hengrui Pharmaceuticals Co Ltd
14.4%
NOVN
31%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd | ||||
|
|
Novartis AG | ||||
ROA
Jiangsu Hengrui Pharmaceuticals Co Ltd
12.9%
NOVN
13.1%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd | ||||
|
|
Novartis AG | ||||
ROIC
Jiangsu Hengrui Pharmaceuticals Co Ltd
30.4%
NOVN
17.8%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd | ||||
|
|
Novartis AG | ||||
ROCE
Jiangsu Hengrui Pharmaceuticals Co Ltd
15.5%
NOVN
23.8%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd | ||||
|
|
Novartis AG | ||||
Solvency Comparison
Jiangsu Hengrui Pharmaceuticals...
Equity Waterfall
Assets
Liabilities
Equity
No Stocks Selected
Compare company's equity waterfall with its competitors.
Balance Sheet Comparison
Stocks Performance
Stocks Performance
600276, NOVN
600276, NOVN
Performance Gap
600276, NOVN
600276, NOVN
Performance By Year
600276, NOVN
600276, NOVN
Loading
No Stocks Selected
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Compare 600276 to other stocks
LLY
Eli Lilly and Co
More expensive
vs Jiangsu Hengrui Pharmaceutical...
JNJ
Johnson & Johnson
More expensive
vs Jiangsu Hengrui Pharmaceutical...
AZN
AstraZeneca PLC
More expensive
vs Jiangsu Hengrui Pharmaceutical...
ROG
Roche Holding AG
Cheaper
vs Jiangsu Hengrui Pharmaceutical...
Select Stock to Compare
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Loading...
Unlock Full Access to Alpha Spread
Create Free Account
